Pulmatrix Q2 FY26 net loss narrows to $1.04 million; operating loss narrows to $1.05 million

Reuters2026/08/13 12:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pulmatrix posted a Q2 net loss of USD 1.04 million, narrowing from USD 1.55 million a year earlier.
Loss per share narrowed to USD 0.29 from USD 0.42.
General and administrative expense fell 32.05% to USD 1.04 million on lower software subscriptions, legal and patent costs, and merger activity.
Cash and cash equivalents totaled USD 2.17 million at June 30, down from USD 4.09 million at Dec. 31.
Form S-4 filed for the planned Eos SENOLYTIX merger, targeted to close in Q3; all clinical development remains on hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pulmatrix Q2 FY26 net loss narrows to $1.04 million; operating loss narrows to $1.05 million

You may also like

Crypto prices